Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LH - Labcorp Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$311.33
DETAILS
HIGH:
$334.00
LOW:
$300.00
MEDIAN:
$300.00
CONSENSUS:
$311.33
UPSIDE:
12.52%
Stock News
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LH or CRL: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026.
Is it the Right Time to Add Labcorp Stock to Your Portfolio?
LH expands specialty testing, acquisitions and AI initiatives to drive growth, but macro pressures and currency headwinds could weigh on results.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA).
LH vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire BURLINGTON,
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).
Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
LH or MEDP: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Labcorp to Present at the Jefferies Global Healthcare Conference
BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
Labcorp (LH) Upgraded to Buy: Here's What You Should Know
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should You Continue to Hold Labcorp Stock in Your Portfolio?
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
Price Targets
Labcorp price target raised to $334 from $332 at Baird
$334.00
(was $255.97)
Eric Coldwell
·
Robert W. Baird
Labcorp price target raised to $300 from $280 at Evercore ISI
$300.00
(was $274.72)
Evercore ISI
Labcorp price target raised to $300 from $270 at Piper Sandler
$300.00
(was $285.30)
David Westenberg
·
Piper Sandler
Labcorp price target raised to $326 from $313 at Baird
$326.00
(was $276.67)
Robert W. Baird
Labcorp price target raised to $313 from $307 at Baird
$313.00
(was $259.18)
Robert W. Baird
Labcorp price target lowered to $320 from $325 at UBS
$320.00
(was $253.74)
Kevin Caliendo
·
UBS
Labcorp price target lowered to $304 from $313 at Baird
$304.00
(was $259.69)
Robert W. Baird
Leerink on Laboratory Corporation of America (LH): 'Sell-off Unwarranted'
$342.00
(was $261.62)
Michael Cherny
·
Leerink Partners
Labcorp price target raised to $325 from $305 at UBS
$325.00
(was $285.93)
UBS
Labcorp price target raised to $320 from $285 at Mizuho
$320.00
(was $283.71)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $320 from $310 at Truist
$320.00
(was $278.42)
Truist Financial
Labcorp price target raised to $305 from $300 at Evercore ISI
$305.00
(was $279.44)
Evercore ISI
Labcorp price target raised to $290 from $275 at Barclays
$290.00
(was $279.06)
Barclays
Labcorp price target raised to $311 from $302 at Baird
$311.00
(was $276.11)
Robert W. Baird
Labcorp price target raised to $305 from $282 at UBS
$305.00
(was $264.96)
Kevin Caliendo
·
UBS
Labcorp price target raised to $275 from $250 at Barclays
$275.00
(was $258.70)
Barclays
Labcorp price target raised to $271 from $249 at Barclays
$271.00
(was $247.86)
Luke Sergott
·
Barclays
Labcorp price target lowered to $240 from $250 at Evercore ISI
$240.00
(was $224.72)
Elizabeth Anderson
·
Evercore ISI
Laboratory Corporation of America (LH) PT Raised to $265 at Jefferies
$265.00
(was $222.22)
Brian Tanquilut
·
Jefferies
Labcorp price target raised to $260 from $240 at BofA
$260.00
(was $236.00)
Michael Ryskin
·
Bank of America Securities